Licensing Agreement for Breast Cancer Drug Onzeald Signed by Nektar Therapeutics, Daiichi Sankyo Europe

Licensing Agreement for Breast Cancer Drug Onzeald Signed by Nektar Therapeutics, Daiichi Sankyo Europe
Nektar Therapeutics and Daiichi Sankyo Europe have announced they signed an agreement for Nektar’s investigational drug therapy Onzeald (etirinotecan pegol) — formerly NKTR-102 – just after the completion of a Phase 3 clinical trial in patients with advanced breast cancer. Breast cancer is the most frequently diagnosed cancer in women worldwide, with approximately 1.7 million new

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *